A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. Placebo-controlled trials showed that the adverse event profile of nintedanib was characterised mainly by gastrointestinal events, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Podolanczuk, Anna J., Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129989/
https://www.ncbi.nlm.nih.gov/pubmed/36928494
http://dx.doi.org/10.1007/s12325-023-02454-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129989/
https://www.ncbi.nlm.nih.gov/pubmed/36928494
http://dx.doi.org/10.1007/s12325-023-02454-9

Ejemplares similares